In patients with hypopituitarism, the high prevalence of MetS is primarily linked to abdominal fat deposition, dyslipidemia, and insulin resistance, with growth hormone replacement therapy showing benefits for lipid profiles and body fat but potentially transiently worsening glucose tolerance (38). The gene discussed is GH1; the disease is metabolic syndrome.